143 related articles for article (PubMed ID: 28535106)
1. Value Tools in Managed Care Decision Making: Current Hurdles and Future Opportunities.
Schafer J; Galante D; Shafrin J
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S21-S27. PubMed ID: 28535106
[TBL] [Abstract][Full Text] [Related]
2. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
3. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
[No Abstract] [Full Text] [Related]
4. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
[TBL] [Abstract][Full Text] [Related]
5. Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology.
Shah-Manek B; Galanto JS; Nguyen H; Ignoffo R
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S13-S20. PubMed ID: 28535103
[TBL] [Abstract][Full Text] [Related]
6. The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making.
Waldeck AR; Botteman MF; White RE; van Hout BA
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S6-S12. PubMed ID: 28535105
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Payer perceptions on the use of economic models in oncology decision making.
Biskupiak J; Oderda G; Brixner D; Burgoyne D; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1560-1567. PubMed ID: 34714111
[No Abstract] [Full Text] [Related]
9. Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.
Frois C; Howe A; Jarvis J; Grice K; Wong K; Zacker C; Sasane R
J Manag Care Spec Pharm; 2019 Feb; 25(2):246-259. PubMed ID: 30698093
[TBL] [Abstract][Full Text] [Related]
10. Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study.
Westrich K; Buelt L; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S28-S33. PubMed ID: 28535102
[TBL] [Abstract][Full Text] [Related]
11. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
12. Current and Future Oncology Management in the United States.
Runyan A; Banks J; Bruni DS
J Manag Care Spec Pharm; 2019 Feb; 25(2):272-281. PubMed ID: 30698085
[TBL] [Abstract][Full Text] [Related]
13. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
[TBL] [Abstract][Full Text] [Related]
14. Payer perceptions and use of value assessment tools in the United States.
Westrich K; Hydery T; Dharbhamalla V; Buelt L; Zheng C; Loo V; Graff J
J Manag Care Spec Pharm; 2023 May; 29(5):582-588. PubMed ID: 37121246
[No Abstract] [Full Text] [Related]
15. The evolution of payer management of oncology drugs in the United States between 2017 and 2022.
Runyan A; Yi J; Honcz J
J Manag Care Spec Pharm; 2023 Oct; 29(10):1138-1149. PubMed ID: 37695273
[No Abstract] [Full Text] [Related]
16. Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience.
Goble JA; Ung B; van Boemmel-Wegmann S; Navarro RP; Parece A
J Manag Care Spec Pharm; 2017 Oct; 23(10):1042-1052. PubMed ID: 28944728
[TBL] [Abstract][Full Text] [Related]
17. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
[TBL] [Abstract][Full Text] [Related]
18. The Current Status of Outcomes-Based Contracting for Manufacturers and Payers: An AMCP Membership Survey.
Duhig AM; Saha S; Smith S; Kaufman S; Hughes J
J Manag Care Spec Pharm; 2018 May; 24(5):410-415. PubMed ID: 29337604
[TBL] [Abstract][Full Text] [Related]
19. Understanding Payer Perspectives on Value in the Use of Pharmaceuticals in the United States.
Brogan AP; Hogue SL; Vekaria RM; Reynolds I; Coukell A
J Manag Care Spec Pharm; 2019 Dec; 25(12):1319-1327. PubMed ID: 31778613
[TBL] [Abstract][Full Text] [Related]
20. Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment.
Dhanda DS; Veenstra DL; Regier DA; Basu A; Carlson JJ
J Manag Care Spec Pharm; 2020 Apr; 26(4):529-537. PubMed ID: 32223606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
